行业对新一代免疫检查点进行“路测”。 - Suppr

Suppr

超能文献

Industry 'road tests' new wave of immune checkpoints.

作者信息

Garber Ken

出版信息

Nat Biotechnol. 2017 Jun 7;35(6):487-488. doi: 10.1038/nbt0617-487.

DOI:10.1038/nbt0617-487

PMID:28591107

Abstract

摘要

相似文献

Industry 'road tests' new wave of immune checkpoints.

Nat Biotechnol. 2017 Jun 7;35(6):487-488. doi: 10.1038/nbt0617-487.

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

Neuro Oncol. 2016 May;18(5):639-48. doi: 10.1093/neuonc/nov292. Epub 2015 Dec 11.

Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.

Dig Dis Sci. 2018 Sep;63(9):2177-2179. doi: 10.1007/s10620-018-5188-z.

Adverse events associated with immune checkpoint inhibitor treatment for cancer.

CMAJ. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870.

The immune checkpoint inhibitors: where are we now?

Nat Rev Drug Discov. 2014 Dec;13(12):883-4. doi: 10.1038/nrd4476. Epub 2014 Oct 27.

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024.

Nobel notes value of basic research for new drugs.

Nature. 2018 Nov;563(7730):184. doi: 10.1038/d41586-018-07307-y.

[Immune-checkpoints: the new anti-cancer immunotherapies].

Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771.

Releasing the Brakes on Cancer Immunotherapy.

N Engl J Med. 2015 Oct 15;373(16):1490-2. doi: 10.1056/NEJMp1510079. Epub 2015 Sep 8.

[The "immune checkpoints", how does it work].

Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1.

引用本文的文献

Aberrant expression of junctional adhesion molecule-A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155.

Cancer Sci. 2021 Feb;112(2):906-917. doi: 10.1111/cas.14734. Epub 2020 Dec 5.

Expression of the immune checkpoint receptor TIGIT in seminoma.

Oncol Lett. 2019 Aug;18(2):1497-1502. doi: 10.3892/ol.2019.10428. Epub 2019 May 31.

Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.

MAbs. 2019 Aug/Sep;11(6):1139-1148. doi: 10.1080/19420862.2019.1629239. Epub 2019 Jun 26.

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Dis Markers. 2019 Jan 10;2019:5160565. doi: 10.1155/2019/5160565. eCollection 2019.

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Front Pharmacol. 2018 Apr 20;9:196. doi: 10.3389/fphar.2018.00196. eCollection 2018.

Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Nat Rev Drug Discov. 2018 Mar;17(3):197-223. doi: 10.1038/nrd.2017.227. Epub 2017 Dec 1.

Adenosine checkpoint agent blazes a trail, joins immunotherapy roster.

Nat Biotechnol. 2017 Sep 11;35(9):805-807. doi: 10.1038/nbt0917-805.

本文引用的文献

The epigenetic landscape of T cell exhaustion.

Science. 2016 Dec 2;354(6316):1165-1169. doi: 10.1126/science.aae0491. Epub 2016 Oct 27.

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Immunity. 2016 Aug 16;45(2):358-73. doi: 10.1016/j.immuni.2016.07.008. Epub 2016 Aug 2.

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001.

Immuno-oncology moves beyond PD-1.

Nat Biotechnol. 2015 Jul;33(7):673-5. doi: 10.1038/nbt0715-673.

Inhibitory receptors as targets for cancer immunotherapy.

Eur J Immunol. 2015 Jul;45(7):1892-905. doi: 10.1002/eji.201344413.

Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Immunity. 2015 Feb 17;42(2):344-355. doi: 10.1016/j.immuni.2015.01.010. Epub 2015 Feb 10.

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Cancer Res. 2012 Feb 15;72(4):917-27. doi: 10.1158/0008-5472.CAN-11-1620. Epub 2011 Dec 20.

Restoring function in exhausted CD8 T cells during chronic viral infection.

Nature. 2006 Feb 9;439(7077):682-7. doi: 10.1038/nature04444. Epub 2005 Dec 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Industry 'road tests' new wave of immune checkpoints.

Nat Biotechnol. 2017 Jun 7;35(6):487-488. doi: 10.1038/nbt0617-487.

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

Neuro Oncol. 2016 May;18(5):639-48. doi: 10.1093/neuonc/nov292. Epub 2015 Dec 11.

Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.

Dig Dis Sci. 2018 Sep;63(9):2177-2179. doi: 10.1007/s10620-018-5188-z.

Adverse events associated with immune checkpoint inhibitor treatment for cancer.

CMAJ. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870.

The immune checkpoint inhibitors: where are we now?

Nat Rev Drug Discov. 2014 Dec;13(12):883-4. doi: 10.1038/nrd4476. Epub 2014 Oct 27.

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024.

Nobel notes value of basic research for new drugs.

Nature. 2018 Nov;563(7730):184. doi: 10.1038/d41586-018-07307-y.

[Immune-checkpoints: the new anti-cancer immunotherapies].

Bull Cancer. 2013 Jun;100(6):601-10. doi: 10.1684/bdc.2013.1771.

Releasing the Brakes on Cancer Immunotherapy.

N Engl J Med. 2015 Oct 15;373(16):1490-2. doi: 10.1056/NEJMp1510079. Epub 2015 Sep 8.

[The "immune checkpoints", how does it work].

Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1.

引用本文的文献

Aberrant expression of junctional adhesion molecule-A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155.

Cancer Sci. 2021 Feb;112(2):906-917. doi: 10.1111/cas.14734. Epub 2020 Dec 5.

Expression of the immune checkpoint receptor TIGIT in seminoma.

Oncol Lett. 2019 Aug;18(2):1497-1502. doi: 10.3892/ol.2019.10428. Epub 2019 May 31.

Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.

MAbs. 2019 Aug/Sep;11(6):1139-1148. doi: 10.1080/19420862.2019.1629239. Epub 2019 Jun 26.

Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.

Dis Markers. 2019 Jan 10;2019:5160565. doi: 10.1155/2019/5160565. eCollection 2019.

Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.

BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors.

Front Pharmacol. 2018 Apr 20;9:196. doi: 10.3389/fphar.2018.00196. eCollection 2018.

Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Nat Rev Drug Discov. 2018 Mar;17(3):197-223. doi: 10.1038/nrd.2017.227. Epub 2017 Dec 1.

Adenosine checkpoint agent blazes a trail, joins immunotherapy roster.

Nat Biotechnol. 2017 Sep 11;35(9):805-807. doi: 10.1038/nbt0917-805.

本文引用的文献

The epigenetic landscape of T cell exhaustion.

Science. 2016 Dec 2;354(6316):1165-1169. doi: 10.1126/science.aae0491. Epub 2016 Oct 27.

Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Immunity. 2016 Aug 16;45(2):358-73. doi: 10.1016/j.immuni.2016.07.008. Epub 2016 Aug 2.

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Immunity. 2016 May 17;44(5):989-1004. doi: 10.1016/j.immuni.2016.05.001.

Immuno-oncology moves beyond PD-1.

Nat Biotechnol. 2015 Jul;33(7):673-5. doi: 10.1038/nbt0715-673.

Inhibitory receptors as targets for cancer immunotherapy.

Eur J Immunol. 2015 Jul;45(7):1892-905. doi: 10.1002/eji.201344413.

Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Immunity. 2015 Feb 17;42(2):344-355. doi: 10.1016/j.immuni.2015.01.010. Epub 2015 Feb 10.

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Cancer Res. 2012 Feb 15;72(4):917-27. doi: 10.1158/0008-5472.CAN-11-1620. Epub 2011 Dec 20.

Restoring function in exhausted CD8 T cells during chronic viral infection.

Nature. 2006 Feb 9;439(7077):682-7. doi: 10.1038/nature04444. Epub 2005 Dec 28.